9 diciembre 2014
A multicenter phase 1 trial of the immune checkpoint blocker ipilimumab found clinical benefit in nearly half of blood cancer patients who had relapsed following allogeneic stem cell transplantation, according to investigators.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/N3MxooIbD4M/141209082306.htm
